Panel Discussion: What Are the Requirements for Validating CNS Biomarkers for Use as Surrogate Endpoints?
Time: 8:15 am
day: Conference Day One
Details:
- Striving for consensus on what is considered a reliable and relevant biomarker of neurodegeneration or neuroinflammation
- Evaluating the ability of amyloid and NfL biomarkers to provide reliable measurements of therapeutic effects on disease neuropathology
- Defining fluid and imaging biomarker standards to be used in the clinic
